Program
baricitinib
Also written as “Baricitinib”, “LY3009104” and “INCB028050”.
Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 546 open or running | phase 4since Apr 12, 2019 | Aug 18, 2010 | Mar 2028phase 3 · NCT05723198 |
| Galvani Bioelectronics | 11 open or running | no phasesince Jul 5, 2021 | Jul 5, 2021 | Jul 2027NCT05003310 |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Aug 9, 2021 | Aug 9, 2021 | none ahead |
| Incepta Pharmaceuticals | 10 open or running | phase 3since Sep 20, 2021 | Sep 20, 2021 | none ahead |
| Incyte | 10 open or running | phase 2since May 13, 2009 | May 13, 2009 | none ahead |
Also a collaborator on its studies: q2-solutions and horus-pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since May 13, 2009.
- Feb 14, 2019Phase 3 study in Lupus Erythematosus, SystemicEli Lilly · NCT03843125 · 1,147 enrolled · United States, Argentina, Australia and more
- Apr 1, 2019Phase 3 study in Alopecia AreataEli Lilly · NCT03899259 · 606 enrolled · United States, Argentina, Australia and more
- Apr 12, 2019Phase 4 study in Arthritis, RheumatoidEli Lilly · NCT03915964 · 2,659 enrolled · United States, Australia, Austria and more
- May 15, 2019Phase 3 study in Dermatitis, AtopicEli Lilly · NCT03952559 · 516 enrolled · Argentina, Australia, Austria and more
- Sep 10, 2019Phase 4 study in Arthritis, RheumatoidEli Lilly · NCT04086745 · 1,050 enrolled · United States
- Sep 11, 20192 phase 3 studiesEli Lilly · NCT04088409, NCT04088396
- Jun 5, 2020Phase 3 study in COVID-19Eli Lilly · NCT04421027 · 1,525 enrolled · United States, Argentina, Brazil and more
- Aug 17, 2020Phase 3 study in Nakajo syndromeEli Lilly · NCT04517253 · 10 enrolled · Japan
- Jul 5, 2021Galvani Bioelectronics's first study: no phase study in Arthritis, RheumatoidNew to Galvani BioelectronicsGalvani Bioelectronics · NCT05003310 · 28 planned · United States, Netherlands
- Aug 9, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05006768 · 30 enrolled · Egypt
- Sep 20, 2021Incepta Pharmaceuticals's first study: phase 3 study in COVID-19New to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT05056558 · Bangladesh
- Oct 8, 2021Phase 3 study in COVID-19Eli Lilly · NCT05074420 · 6 enrolled · United States, Brazil, Mexico and more
- Feb 3, 2023Phase 3 study in AlopeciaEli Lilly · NCT05723198 · 595 planned · United States, Argentina, Australia and more
- Oct 27, 20252 phase 3 studies in Diabetes Mellitus, Type 1Eli Lilly · NCT07222332, NCT07222137
Ahead
- Jul 2027Primary completion: no phase study in Arthritis, RheumatoidGalvani Bioelectronics · NCT05003310
- Mar 2028Primary completion: phase 3 study in AlopeciaEli Lilly · NCT05723198
- Jul 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07222332
- Jul 2031Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07222137
TargetBeta
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
Studies
All 58 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07222332Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more | 3 | Recruiting | Eli Lilly | Jul 2028 | 300 |
| NCT07222137Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more | 3 | Recruiting | Eli Lilly | Jul 2031 | 150 |
| NCT05723198Alopecia · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Mar 2028 | 595 |
| NCT05074420COVID-19 · United States, Brazil, Mexico and more | 3 | Terminated | Eli Lilly | Sep 5, 2024 | 6 |
| NCT05056558COVID-19 · Bangladesh | 3 | Withdrawn | Incepta Pharmaceuticals | Jul 30, 2025 | 0 |
| NCT05006768Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Jun 3, 2021 | 30 |
| NCT05003310Arthritis, Rheumatoid · United States, Netherlands | – | Recruiting | Galvani Bioelectronics | Jul 2027 | 28 |
| NCT04517253Nakajo syndrome · Japan | 3 | Terminated | Eli Lilly | Apr 4, 2023 | 10 |
| NCT04421027COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Feb 12, 2021 | 1,525 |
| NCT04088409Uveitis · France, Germany, Italy and more | 3 | Active, not recruiting | Eli Lilly | Jul 17, 2023 | 30 |
| NCT04088396Arthritis, Juvenile · Argentina, Belgium, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Oct 2026 | 58 |
| NCT04086745Arthritis, Rheumatoid · United States | 4 | Completed | Eli Lilly | May 19, 2025 | 1,050 |
| NCT03952559Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Apr 24, 2022 | 516 |
| NCT03915964Arthritis, Rheumatoid · United States, Australia, Austria and more | 4 | Completed | Eli Lilly | May 28, 2025 | 2,659 |
| NCT03899259Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jan 24, 2021 | 606 |
| NCT03843125Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Terminated | Eli Lilly | Apr 1, 2022 | 1,147 |
| NCT03773978Arthritis, Juvenile · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Jan 26, 2022 | 220 |
| NCT03773965Arthritis, Juvenile · Argentina, Australia, Austria and more | 3 | Recruiting | Eli Lilly | Jul 2031 | 190 |
| NCT03742973Liver Cirrhosis, Biliary · United States, Puerto Rico | 2 | Terminated | Eli Lilly | Sep 26, 2019 | 2 |
| NCT03733301Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Jul 29, 2019 | 329 |
| NCT03616964Lupus Erythematosus, Systemic · United States, Argentina, Chile and more | 3 | Completed | Eli Lilly | Sep 24, 2021 | 778 |
| NCT03616912Lupus Erythematosus, Systemic · United States, Australia, Austria and more | 3 | Terminated | Eli Lilly | Nov 1, 2021 | 830 |
| NCT03570749Alopecia Areata · United States, Japan, Mexico and more | 3 | Completed | Eli Lilly | Feb 2, 2021 | 784 |
| NCT03559270Dermatitis, Atopic · United States, Canada, Puerto Rico | 3 | Terminated | Eli Lilly | Oct 14, 2021 | 374 |
| NCT03435081Dermatitis, Atopic · United States, Canada, Puerto Rico | 3 | Completed | Eli Lilly | Dec 9, 2019 | 440 |
| NCT03428100Dermatitis, Atopic · Austria, Belgium, Brazil and more | 3 | Completed | Eli Lilly | Nov 25, 2019 | 463 |
| NCT03334435Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Sep 21, 2020 | 1,645 |
| NCT03334422Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Dec 12, 2018 | 615 |
| NCT03334396Dermatitis, Atopic · Czechia, Denmark, France and more | 3 | Completed | Eli Lilly | Dec 6, 2018 | 660 |
| NCT03212638Healthy · Singapore | 1 | Completed | Eli Lilly | Jul 31, 2017 | 42 |
| NCT02758613Healthy · China | 1 | Completed | Eli Lilly | Jul 2016 | 33 |
| NCT02708095Lupus Erythematosus, Systemic · United States, Argentina, Austria and more | 2 | Completed | Eli Lilly | Oct 12, 2017 | 314 |
| NCT02576938Dermatitis, Atopic · United States, Japan | 2 | Completed | Eli Lilly | Feb 2017 | 124 |
| NCT02340104Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Feb 2015 | 8 |
| NCT02265705Arthritis, Rheumatoid · Argentina, Brazil, China | 3 | Completed | Eli Lilly | May 2017 | 290 |
| NCT02263911Healthy Participants · Japan | 1 | Completed | Eli Lilly | Dec 2014 | 16 |
| NCT01968057Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Dec 2013 | 18 |
| NCT01937026Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Nov 2013 | 18 |
| NCT01925144Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Nov 2013 | 30 |
| NCT01924299Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Nov 2013 | 36 |
| NCT01910311Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Oct 2013 | 18 |
| NCT01896726Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Oct 2013 | 20 |
| NCT01885078Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Nov 12, 2020 | 2,877 |
| NCT01870388Liver Diseases · United States | 1 | Completed | Eli Lilly | Jul 2013 | 16 |
| NCT01859078Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Aug 2013 | 28 |
| NCT01721057Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Sep 2014 | 684 |
| NCT01721044Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 2014 | 527 |
| NCT01711359Arthritis, Rheumatoid · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | Feb 2015 | 588 |
| NCT01710358Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Mar 2015 | 1,307 |
| NCT01683409Diabetic Nephropathies · United States, Japan, Mexico and more | 2 | Completed | Eli Lilly | Sep 2014 | 130 |
| NCT01536951Healthy Participants · United States | 1 | Completed | Eli Lilly | May 2013 | 62 |
| NCT01490632Psoriasis · United States, Canada, Japan and more | 2 | Completed | Eli Lilly | Dec 2012 | 271 |
| NCT01469013Arthritis, Rheumatoid · Japan | 2 | Completed | Eli Lilly | Nov 2012 | 145 |
| NCT01398475Arthritis, Rheumatoid · Singapore | 1 | Completed | Eli Lilly | Sep 2011 | 15 |
| NCT01299285Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Mar 2011 | 6 |
| NCT01247350Healthy Volunteer · United States | 1 | Completed | Eli Lilly | Apr 2011 | 34 |
| NCT01185353Arthritis, Rheumatoid · United States, Croatia, Czechia and more | 2 | Completed | Eli Lilly | Dec 2011 | 301 |
| NCT00902486Arthritis, Rheumatoid · United States, Czechia | 2 | Completed | Incyte | Jun 2010 | 127 |
How it is read
Names in the registry
- “Baricitinib”, 53 entries
- “LY3009104”, 5 entries
- “INCB028050”, 3 entries
- “Barcimiant”, 1 entry
- “Baricitinib suspension”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 13 studies
- Dermatitis, Atopic, 9 studies
- Lupus Erythematosus, Systemic, 4 studies
- COVID-19, 3 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.